(Q28292463)

2

0 references

Susan Kaufman

4

0 references

Jürgen Mestan

5

0 references

Markus Wartmann

6

0 references

Richard Woodman

8

0 references

Neil Gallagher

9

0 references

Paul W. Manley

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20817538

7 July 2024

Sandra W. Cowan-Jacob

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20817538

7 July 2024

language of work or name

English

0 references

publication date

1 October 2010

0 references

14 August 2010

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20817538

full work available at URL

7 July 2024

https://api.elsevier.com/content/article/PII:S0968089610007716?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

https://api.elsevier.com/content/article/PII:S0968089610007716?httpAccept=text/plain

7 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Bioorganic & Medicinal Chemistry

7 July 2024

published in

0 references

volume

18

0 references

issue

19

0 references

page(s)

6977-86

0 references

cites work

Chemical Similarity Searching

1 reference

COCI

https://opencitations.net/index/coci/api/v1/citations/10.1021/CI9800211

Chronic myeloid leukaemia as a model of disease evolution in human cancer

12 September 2021

4

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment

7 July 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

7 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

7 July 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

7 July 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

7 July 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

7 July 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

7 July 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases

7 July 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

7 July 2024

16

62

4236

Nagar

2002

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Imatinib: a selective tyrosine kinase inhibitor

7 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia

7 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment

7 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Selected concepts and investigations in compound classification, molecular descriptor analysis, and virtual screening

7 July 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

7 July 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Molecular field extrema as descriptors of biological activity: definition and validation.

7 July 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib

7 July 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein

7 July 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways

7 July 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

7 July 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors

7 July 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Assessing the ability of chemical similarity measures to discriminate between active and inactive compounds

7 July 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

An evaluation of structural descriptors and clustering methods for use in diversity selection.

7 July 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Database searching for compounds with similar biological activity using short binary bit string representations of molecules

7 July 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Do structurally similar molecules have similar biological activity?

7 July 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Acid-base profiling of imatinib (gleevec) and its fragments.

7 July 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Active transport of imatinib into and out of cells: implications for drug resistance

7 July 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

7 July 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

siRNA-mediated knock-down of P-glycoprotein expression reveals distinct cellular disposition of anticancer tyrosine kinases inhibitors

7 July 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

7 July 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib

7 July 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters.

7 July 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib

7 July 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

7 July 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

7 July 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT).

7 July 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

7 July 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

7 July 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

7 July 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

7 July 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib

7 July 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

7 July 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms.

7 July 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Intramuscular edema as a complication of treatment with imatinib

7 July 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Unmasking of a protective tumor necrosis factor receptor I-mediated signal in the collagen-induced arthritis model

7 July 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

There is no such thing as 'diversity'!

7 July 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

7 July 2024

62

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

High-throughput lipophilicity measurement with immobilized artificial membranes

7 July 2024

63

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties

7 July 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.BMC.2010.08.026

7 July 2024

Identifiers

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017